{
    "organizations": [],
    "uuid": "a3958932eae2c120cd8e17b0b2aad7ffa866c8b3",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-kalytera-terminates-pre-clinical-p/brief-kalytera-terminates-pre-clinical-programs-in-bone-disease-idUSFWN1RQ0K0",
    "ord_in_thread": 0,
    "title": "BRIEF-Kalytera Terminates Pre Clinical Programs In Bone Disease",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 13 (Reuters) - Kalytera Therapeutics Inc:\n* COMPANY TO FOCUS RESOURCES ON GVHD AND PAIN PROGRAMS * DETERMINED INVESTMENTS OF TIME, RESOURCES IN THESE PROGRAMS NOT APPROPRIATE GIVEN OTHER OPPORTUNITIES IN DEVELOPMENT PIPELINE\n* TERMINATED PROGRAMS WERE EVALUATING THREE SYNTHETIC ENDOCANNABINOID COMPOUNDS, KAL436, KAL439 AND KAL671\n* CLINICAL PROGRAMS DOES NOT REFLECT A NEGATIVE ASSESSMENT OF COMPOUNDS LICENSED FROM YISSUM\n* DECISION TO TERMINATE THESE PROGRAMS IS PART OF OVERALL STRATEGY TO FOCUS ON DEVELOPMENT OF CANNABINOID THERAPEUTICS Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-04-13T21:06:00.000+03:00",
    "crawled": "2018-04-14T13:26:20.004+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "kalytera",
        "therapeutic",
        "inc",
        "company",
        "focus",
        "resource",
        "gvhd",
        "pain",
        "program",
        "determined",
        "investment",
        "time",
        "resource",
        "program",
        "appropriate",
        "given",
        "opportunity",
        "development",
        "pipeline",
        "terminated",
        "program",
        "evaluating",
        "three",
        "synthetic",
        "endocannabinoid",
        "compound",
        "kal436",
        "kal439",
        "kal671",
        "clinical",
        "program",
        "reflect",
        "negative",
        "assessment",
        "compound",
        "licensed",
        "yissum",
        "decision",
        "terminate",
        "program",
        "part",
        "overall",
        "strategy",
        "focus",
        "development",
        "cannabinoid",
        "therapeutic",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}